Sex Selection Moves to Consumer Culture
By Marcy Darnovsky,
Genetic Crossroads
| 08. 20. 2003
Ads for "Family Balancing" in The New York Times
Several times over the past few months, a small
but striking ad from a Virginia-based fertility clinic has appeared
in the Sunday Styles section of The New York Times. Alongside
a smiling baby, its boldface headline asks, "Do You Want
To Choose the Gender Of Your Next Baby?"
If so, the ad continues, you can join "prospective parents…from
all over the world" who come to the Genetics & IVF
Institute (GIVF) for an "exclusive scientifically-based
sperm sorting gender selection procedure." The technique,
known by the trademarked name MicroSort, is offered as a way
to choose a girl or boy either for the "prevention of genetic
diseases" (selecting against the sex affected by an X-linked
or Y-linked condition) or for "family balancing" (selecting
for a girl in a family that already has one or more boys, or
vice versa).
GIVF
has been promoting MicroSort on its website for several years,
and a few other fertility clinics offer other "family balancing"
methods online. But the MicroSort ads in The New York Times
represent a bolder and higher-profile approach. They mark the...
Related Articles
By Maia Hibbett, Wired | 09.09.2026
THE INSTAGRAM POST, precision-guided by sex and age, had zeroed in on its target. Yuchen Tu is a conservatory-trained viola player from Chongqing, China, a lover of science fiction, and an aspiring member of the US Army Reserve Officer Training...
By Kylie Baldwin and Stuart Lavery, BioNews | 09.14.2026
In August, the Royal College of Obstetricians and Gynaecologists (RCOG) published their Scientific Impact Paper on 'social' or 'elective' egg freezing, a technology which increasing numbers of women are turning to in a bid to extend their fertile window and...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Claire Robinson and Jonathan Matthews, Guest Contributors
| 08.25.2026
This is an excerpt of an article originally published on August 1, 2026 at GMWatch.
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool – in this case a base editor – into her spinal fluid, she died of a severe immune reaction linked to the therapy.
Just...